Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer
Medical Xpress
February 27, 2026
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery alone, according to a study published online Feb. 18 in the New England Journal of Medicine.
Verticals
healthmedical
Originally published on Medical Xpress on 2/27/2026